integrative organs systems scientists and drug discovery: the link between big pharma and academia

23
Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative Pharmacology Global Pharmaceutical Discovery Abbott Laboratories

Upload: nuncio

Post on 28-Jan-2016

38 views

Category:

Documents


0 download

DESCRIPTION

Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia. Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative Pharmacology Global Pharmaceutical Discovery Abbott Laboratories. Integrative Organs Systems Scientists in Pharmaceutical Discovery. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Glenn A. Reinhart, Ph.D.Senior Group LeaderIntegrative PharmacologyGlobal Pharmaceutical DiscoveryAbbott Laboratories

Page 2: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Integrative Organs Systems Scientists inPharmaceutical Discovery

• The drug discovery process continues to exploit and develop new, reductionist and high throughput technologies in the search for novel lead molecules for the treatment of new disease targets.

• To move toward clinical development a compound must demonstrate key in vivo characteristics:

– efficacy and specificity in disease state models

– safety, safety, safety

– adequate pharmacokinetic, pharacodynamic and metabolic profiles

Page 3: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Drug Discovery: the Path to Clinical Development

Idea

Target Identification

Target Validation

Lead Optimization

Drug Development Candidate

Clinical Development

Page 4: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Molecular Biology

Organizational Structure“Matrix”

PharmacologyMedicinal Chemistry

ProjectTeams

PK / ADME ToxicologySafety

Pharmacology

Page 5: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Organizational Structure“Project Team”

ProjectTeams

PK / ADME ToxicologyIntegrative

Pharmacology

Therapeutic Area VP

Page 6: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Organizational Structure“Modified Project Team”

ProjectTeams

PK / ADME ToxicologyIntegrative

Pharmacology

Therapeutic Area VP

In Vivo Pharmacology

Page 7: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Integrative Scientists:Hallmarks of Success

• Strong scientific ability

• Excellent communication skills

• Critical thinking skills

• Flexible expertise

• Depth and Breadth

Top tier, well-published, competitive scientists

Page 8: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Industry SurveyComparing the Presence of Integrative & Organs

Systems vs. Reductionist Scientists: 1991 and 2001

Definitions• Integrative & Organs Systems Scientists (IOSS) are functionally defined as

scientists focusing on scientific approaches whose aim is to understand how intact biological systems function at the level of whole animals, organs, and organ systems (but not in the clinic) or approaches aimed at identifying or describing potential “clinical’ effects using whole animals, organs, and organ systems.

• Reductionist Scientists are functionally defined as scientists focusing on scientific approaches whose aim is to identify molecular and cellular events, studied in purified form or in isolated systems and include genomics, proteomics, biochemistry, and cell biology.

Page 9: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Industry SurveyComparing the Presence of Integrative & Organs

Systems vs. Reductionist Scientists: 1991 and 2001

• Distributed via email to > 120 scientists (“Industry Scientists” per EB 2002 registration) AND to members of the Safety Pharmacology Society.

• 12 respondents:– 6-7 companies represented– Big Pharma– CROs– USA, France, Germany

• Most departments represented likely have an in vivo focus

Page 10: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Industry SurveyComparing the Presence of Integrative & Organs

Systems vs. Reductionist Scientists: 1991 and 2001

Respondents

What title best describes you current position within your Department in 2001?

– Vice President 1

– Division Chief 1

– Department Head/Director 6

– Department Manager 1

– Group/Team Leader 0

– Lab Manager 2

Page 11: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7N

um

be

r o

f R

es

po

nd

en

ts

NA 1-12 13-24 25-36 37-48 >49

Number of Employees

IOSS-1991

IOSS-2001

Number of Employees in Department

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Employees

Reductionist 1991

Reductionist 2001

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Employees

Other 1991

Other 2001

Page 12: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Employees with Doctorates

1991

2001

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Employees with Masters

1991

2001

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Employees with Bachelor's

1991

2001

Numbers of Employees With

Degrees

Page 13: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7

8N

um

be

r o

f R

es

po

nd

en

ts

NA 1-12 13-24 25-36 37-48 >49

Number of Open IOSS Positions

1991

2001

0

1

2

3

4

5

6

7

8

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Open "Other" Positions

1991

2001

Number of Open Positions

0

1

2

3

4

5

6

7

8

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Open Reductionist Positions

1991

2001

Page 14: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7

8

9

Nu

mb

er

of

Re

sp

on

de

nts

NA <1 1-3 4-6 7-9 10-20 >20

Average Length of Employment (years)

IOSS 1991

IOSS 2001

Reductionist 1991

Reductionist 2001

Other 1991

Other 2001

Length of Employment

Page 15: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia
Page 16: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

How many months to find qualified applicants?

0123456789

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24

IOSS

Reductionist

0

1

2

3

4

5

6

7

8

9

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24

0

12

34

56

78

9

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24

Others

In General

0

1

2

3

4

5

6

7

8

9

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24

Page 17: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7

Nu

mb

er o

f R

esp

on

den

ts

NA 1-12 13-24 25-36 37-48 >49

Number of Applicants

IOSS 1991

IOSS 2001

Reductionist 1991

Reductionist 2001

Average number of applicants per open position (total applicants)

Page 18: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Applicants

Applicants with Graduate Degrees

19912001

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Applicants

Applicants with Bachelor's Degrees

1991

2001

Average number of applicants per open position:

IOS Scientists

Page 19: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

00.5

11.5

22.5

33.5

4

4.55

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Applicants

Applicants with Graduate Degrees

19912001

0

1

2

3

4

5

6

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of Applicants

Applicants with Bachelor's Degrees

19912001

Average number of applicants per open position:

Reductionist Scientists

Page 20: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7

8

9

10

Nu

mb

er

of

Re

sp

on

de

nts

NA 1-12 13-24 25-36 37-48 >49

Number of IOSS Applicants

Qualified 1991

Unqualified 1991

Qualified 2001

Unqualified 2001

Per open IOSS position: qualified vs. unqualified applicants?

Page 21: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

0

1

2

3

4

5

6

7

Nu

mb

er

of

Re

sp

on

de

nts

NA YES NO

IOSS - 1991

IOSS - 2001

Reductionist - 1991

Reductionist - 2001

Are salary adjustments made during recruitment?

Page 22: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia

Industry SurveyComparing the Presence of Integrative & Organs

Systems vs. Reductionist Scientists: 1991 and 2001

Based on the Departments represented in the survey, it is suggested that in Industry:

• A greater number of positions, both filled and open, may exist for BS - MS and Ph.D. level IOS Scientists relative to 1991.

• A greater number of positions for IOS Scientists remain open compared to 1991.

• Duration of recruiting is greater for IOSS than Reductionist or other scientists and compared to 1991. Fewer applicants per position.

• More ‘unqualified’ candidates may be applying for IOSS positions.

• At present, IOS Scientists appear to have longer duration of employment (same company) than Reductionist or other scientists.

Page 23: Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia